Search

Author/Creator Goodman, Andrew D

1. A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment. (April 2022)

Authors:
Cohen, Jeffrey A; Cameron, Michelle H; Goldman, Myla D; Goodman, Andrew D; Miller, Aaron E; Rollins, Anne; Llorens, Lily; Patni, Rajiv; Elfont, Robert; Johnson, Reed
Journal:
Multiple sclerosis
Issue:
Volume 28:Number 5(2022)
Page Start:
817
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study. (October 2022)

Authors:
Ford, Corey C; Cohen, Jeffrey A; Goodman, Andrew D; Lindsey, John W; Lisak, Robert P; Luzzio, Christopher; Pruitt, Amy; Rose, John; Rus, Horea; Wolinsky, Jerry S; Kadosh, Shaul E; Bernstein-Hanlon, Emily; Stark, Yafit; Alexander, Jessica K
Journal:
Multiple sclerosis
Issue:
Volume 28:Number 11(2022)
Page Start:
1729
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials. (September 2015)

Authors:
Goodman, Andrew D; Bethoux, Francois; Brown, Theodore R; Schapiro, Randall T; Cohen, Ron; Marinucci, Lawrence N; Henney, Herbert R; Blight, Andrew R
Other Names:
Agius M non-byline-author.; Arnason BGW non-byline-author.; Bethoux FA non-byline-author.; Bever CT non-byline-author.; Bowen JD non-byline-author.; Brown TR non-byline-author.; Dietrich DW non-byline-author.; Edwards K non-byline-author.; Freedman MS non-byline-author.; Freedman M non-byline-aut...
Journal:
Multiple sclerosis
Issue:
Volume 21:Number 10(2015)
Page Start:
1322
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis. (November 2021)

Authors:
Fox, Robert J; Raska, Paola; Barro, Christian; Karafa, Matthew; Konig, Victoria; Bermel, Robert A; Chase, Marianne; Coffey, Christopher S; Goodman, Andrew D; Klawiter, Eric C; Naismith, Robert T; Kuhle, Jens
Journal:
Multiple sclerosis
Issue:
Volume 27:Number 13(2021)
Page Start:
2014
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis. (August 2021)

Authors:
Bermel, Robert A; Fedler, Janel K; Kaiser, Peter; Novalis, Cindy; Schneebaum, Jeff; Klingner, Elizabeth A; Williams, Dawn; Yankey, Jon W; Ecklund, Dixie J; Chase, Marianne; Naismith, Robert T; Klawiter, Eric C; Goodman, Andrew D; Coffey, Christopher S; Fox, Robert J
Journal:
Multiple sclerosis
Issue:
Volume 27:Number 9(2021)
Page Start:
1384
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗